Abstract
Objective: To determine the safety of blood-brain barrier (BBB) opening in Alzheimer’s disease (AD) patients using focused ultrasound (FUS).
Background: Progressive amyloid deposition and cognitive decline characterize AD. In preclinical studies, the BBB with FUS reduced plaque. In this Phase-1 trial, we tested the safety of repeated BBB opening with FUS in AD patients.
Design/Methods: Probable AD patients with mild to moderate dementia symptoms were screened. A high amyloid burden was defined by a standardized uptake value 25% greater than the cerebellum using amyloid positron emission tomography (PET). BBB was opened in five different locations with a high amyloid burden at three time-points two weeks apart. The primary outcome variable was the absence of cognitive decline, hemorrhage, new onset of seizures, or neurological deficits. We also assessed BBB opening (with dynamic contrast imaging) and postoperative PET amyloid levels.
Results: Ten patients were screened, six were enrolled, and five were treated. The targeted brain regions included the hippocampus, entorhinal cortex, thalamus, frontal cortex, parietal cortex. No hemorrhage and cerebral edema were observed. BBB opening was focal, immediate, and no contrast enhancement was observed one day postoperative. No serious adverse events were recorded. A total of seven adverse events were reported, most commonly confusion. Two patients reported worsening in cognition at day-1 and five weeks after treatment, respectively. The amyloid reduction varied between 1–15% from baseline without significant differences between different tissue types (gray versus white matter).
Conclusions: BBB opening with FUS is safe and feasible in AD patients. There is the initial evidence of amyloid reduction. This strategy needs further testing in a larger cohort as a potential therapeutic for AD.
Disclosure: Vibhor Krishna has nothing to disclose. Francesco Sammartino has nothing to disclose. Michael Knopp has nothing to disclose. Katherine Binzel has nothing to disclose. Dr. Scharre has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BrainTest, Inc. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Vascular Scientific. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acadia. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Scharre has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Hickman & Lowder Co.. The institution of Dr. Scharre has received research support from InSightec. The institution of Dr. Scharre has received research support from Alzheimer’s Therapeutic Research Institute (ATRI). The institution of Dr. Scharre has received research support from Eisai. The institution of Dr. Scharre has received research support from vTv Therapeutics. The institution of Dr. Scharre has received research support from National Institute of Health. The institution of Dr. Scharre has received research support from Eli Lilly. The institution of Dr. Scharre has received research support from Johns Hopkins. The institution of Dr. Scharre has received research support from Biogen. The institution of Dr. Scharre has received research support from Roche. The institution of Dr. Scharre has received research support from AZ Therapies. The institution of Dr. Scharre has received research support from Biohaven. The institution of Dr. Scharre has received research support from Novartis. The institution of Dr. Scharre has received research support from Avanir. The institution of Dr. Scharre has received research support from PrecisionMed, Inc. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
